LeMaitre Vascular, Inc. (NASDAQ:LMAT) Announces Quarterly Dividend of $0.25

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Thursday, February 19th. Stockholders of record on Thursday, March 12th will be given a dividend of 0.25 per share by the medical instruments supplier on Thursday, March 26th. This represents a c) annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Thursday, March 12th. This is a 25.0% increase from LeMaitre Vascular’s previous quarterly dividend of $0.20.

LeMaitre Vascular has raised its dividend payment by an average of 0.2%annually over the last three years and has increased its dividend every year for the last 14 years. LeMaitre Vascular has a dividend payout ratio of 42.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $1.00 annual dividend with an expected future payout ratio of 46.1%.

LeMaitre Vascular Price Performance

LMAT opened at $110.07 on Tuesday. The stock has a fifty day moving average of $89.84 and a 200-day moving average of $88.81. The company has a quick ratio of 10.95, a current ratio of 12.89 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $2.51 billion, a P/E ratio of 43.85, a PEG ratio of 3.09 and a beta of 0.66. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. The firm had revenue of $64.45 million for the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The business’s quarterly revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.49 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

Analyst Ratings Changes

LMAT has been the subject of a number of research analyst reports. Citizens Jmp lifted their price target on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday, February 26th. Zacks Research downgraded LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Weiss Ratings cut LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, February 24th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research report on Monday, November 10th. Three research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Hold” and a consensus target price of $105.80.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.